Shots:

• The SURPASS-1 study involves assessing the efficacy & safety of Tirzepatide as monothx. (5/10/15 mg) vs PBO in 478 patients in the ratio (1:1:1:1) with T2D inadequately controlled with diet & exercise alone across US- Mexico- India & Japan
• Results: A1C reduction: (-1.87% /-1.89%/-2.07% vs +0.04%); Weight reduction: (-7.0/-7.8/-9.5kg vs-0.7 kg); percentage of participants achieving A1C <7%- (87%/92%/88% vs 20%); participants achieving A1C <5- (7%: 34% /31%/52% vs 1%) respectively- published in the Lancet
• The therapy also showed improvements in a change in FSG from baseline @40 wks. with additional improvements in a change in 2 hrs. post-meal glucose values across all 3 doses

  | Ref: Eli Lilly | Image: The Indian Express